TY  - JOUR
A1  - Gordon, Sarah
A1  - Daneshian, Mardas
A1  - Bouwstra, Joke
A1  - Caloni, Francesca
A1  - Constant, Samuel
A1  - Davies, Donna E.
A1  - Dandekar, Gudrun
A1  - Guzman, Carlos A.
A1  - Fabian, Eric
A1  - Haltner, Eleonore
A1  - Hartung, Thomas
A1  - Hasiwa, Nina
A1  - Hayden, Patrick
A1  - Kandarova, Helena
A1  - Khare, Sangeeta
A1  - Krug, Harald F.
A1  - Kneuer, Carsten
A1  - Leist, Marcel
A1  - Lian, Guoping
A1  - Marx, Uwe
A1  - Metzger, Marco
A1  - Ott, Katharina
A1  - Prieto, Pilar
A1  - Roberts, Michael S.
A1  - Roggen, Erwin L.
A1  - Tralau, Tewes
A1  - van den Braak, Claudia
A1  - Walles, Heike
A1  - Lehr, Claus-Michael
T1  - Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology
JF  - ALTEX: Alternatives to Animal Experimentation
N2  - Models of the outer epithelia of the human body namely the skin, the intestine and the lung have found valid applications in both research and industrial settings as attractive alternatives to animal testing. A variety of approaches to model these barriers are currently employed in such fields, ranging from the utilization of ex vivo tissue to reconstructed in vitro models, and further to chip-based technologies, synthetic membrane systems and, of increasing current interest, in silico modeling approaches. An international group of experts in the field of epithelial barriers was convened from academia, industry and regulatory bodies to present both the current state of the art of non-animal models of the skin, intestinal and pulmonary barriers in their various fields of application, and to discuss research-based, industry-driven and regulatory-relevant future directions for both the development of new models and the refinement of existing test methods. Issues of model relevance and preference, validation and standardization, acceptance, and the need for simplicity versus complexity were focal themes of the discussions. The outcomes of workshop presentations and discussions, in relation to both current status and future directions in the utilization and development of epithelial barrier models, are presented by the attending experts in the current report.
KW  - on-a-chip
KW  - asthmatic bronchial epithelium
KW  - vesicle-based barrier
KW  - pulmonary drug-delivery
KW  - epithelial cell culture
KW  - cytotoxicity
KW  - transport studies
KW  - permeability
KW  - in vitro models
KW  - air-liquid interface
KW  - respiratory syncytial virus
KW  - reconstructed human epidermis
KW  - artificial membrane-permeability
KW  - embryonic stem cells
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144275
VL  - 32
IS  - 4
ER  - 
TY  - JOUR
A1  - Lehners, Nicola
A1  - Tabatabai, Julia
A1  - Prifert, Christiane
A1  - Wedde, Marianne
A1  - Puthenparambil, Joe
A1  - Weissbrich, Benedikt
A1  - Biere, Barbara
A1  - Schweiger, Brunhilde
A1  - Egerer, Gerlinde
A1  - Schnitzler, Paul
T1  - Long-Term Shedding of Influenza Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial Epidemiology in Patients with Hematological Disorders
JF  - PLoS ONE
N2  - Respiratory viruses are a cause of upper respiratory tract infections (URTI), but can be associated with severe lower respiratory tract infections (LRTI) in immunocompromised patients. The objective of this study was to investigate the genetic variability of influenza virus, parainfluenza virus and respiratory syncytial virus (RSV) and the duration of viral shedding in hematological patients. Nasopharyngeal swabs from hematological patients were screened for influenza, parainfluenza and RSV on admission as well as on development of respiratory symptoms. Consecutive swabs were collected until viral clearance. Out of 672 tested patients, a total of 111 patients (17%) were infected with one of the investigated viral agents: 40 with influenza, 13 with parainfluenza and 64 with RSV; six patients had influenza/RSV or parainfluenza/RSV co-infections. The majority of infected patients (n = 75/111) underwent stem cell transplantation (42 autologous, 48 allogeneic, 15 autologous and allogeneic). LRTI was observed in 48 patients, of whom 15 patients developed severe LRTI, and 13 patients with respiratory tract infection died. Phylogenetic analysis revealed a variety of influenza A(H1N1)pdm09, A(H3N2), influenza B, parainfluenza 3 and RSV A, B viruses. RSV A was detected in 54 patients, RSV B in ten patients. The newly emerging RSV A genotype ON1 predominated in the study cohort and was found in 48 (75%) of 64 RSV-infected patients. Furthermore, two distinct clusters were detected for RSV A genotype ON1, identical RSV G gene sequences in these patients are consistent with nosocomial transmission. Long-term viral shedding for more than 30 days was significantly associated with prior allogeneic transplantation (p = 0.01) and was most pronounced in patients with RSV infection (n = 16) with a median duration of viral shedding for 80 days (range 35–334 days). Long-term shedding of respiratory viruses might be a catalyzer of nosocomial transmission and must be considered for efficient infection control in immunocompromised patients.
KW  - viral shedding
KW  - influenza virus
KW  - parainfluenza virus
KW  - respiratory syncytial virus
KW  - hematological disorders
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-167243
VL  - 11
IS  - 2
ER  -